Table 4 |
|||
|
Rates of myocardial infarction and stroke in the all-control population |
|||
|
All-control population n = 4,199 |
|||
|
Control n = 1,555 |
Tocilizumab 4 mg/kg + DMARDs n = 774 |
Tocilizumab 8 mg/kg + DMARDs n = 1,870 |
|
|
|
|||
|
Rate/100 PY (95% CI), (number of events) |
|||
|
Myocardial infarction |
0.49 (0.13, 1.24), (4) |
0.18 (0.00, 0.99), (1) |
0.17 (0.02, 0.61), (2) |
|
Stroke |
0.24 (0.03, 0.88), (2) |
0.0 |
0.33 (0.09, 0.86), (4) |
|
|
|||
|
CI, confidence interval; DMARD, disease-modifying antirheumatic drug; PY, patient-years. Multiple occurrences of the same adverse event in individual patients were counted. |
|||
|
Schiff et al. Arthritis Research & Therapy 2011 13:R141 doi:10.1186/ar3455 |
|||
